Page-TitlePRODUCTS
non-opioid pain relief delivery

WE ARE TARGETING PAIN AT ITS SOURCE

Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from the postoperative pain to the treatment of acute and chronic pain.

SubheadINNOVATIVEDRUG-DELIVERYTECHNOLOGIES
patch in a can

Transdermal metered-dose spray

VIRPAX has licensed a patented aerosol-based system that delivers active pharmaceutical ingredients (API) as a Patch-in-a-Can. This proprietary spray formulation delivers the API as a film and can be manipulated to deliver API immediately or over an extended time from 12 to 24 hours.


CONVENIENT

No messy cream or gels that can be rubbed off by clothing or physical contact


AESTHETICALLY APPEALING

Invisible once applied


EASILY OPTIMIZABLE

Use with metered-dose delivery valves

“I feel that a large number of pain patients will prefer the spray over patches and ointment and am really glad to see this new technology that will allow more precise application while using lesser active ingredient.”

SANJAY GUPTA
President, American Pain Association

Liposomal in Hydrogel encapsulation

Our patented liposomal gel encapsulates a high dose of local anesthetic in hydrogel, cholesterol, and other “GRAS” lipids. A single dose can be injected at the surgical site to provide a prolonged postoperative analgesia effect for up to 96 hours. This may enhance recovery protocols, reduce the length of a patient’s hospital stay post-surgery, and significantly reduce or eliminate the use of opioids.


PROLONGED EFFECTS

Postoperative analgesia effect for up to 96 hours


EFFICIENT DRUG-DELIVERY

Fast onset of action and peak analgesic activity in post-operative setting


IMPROVED QUALITY OF CARE

Reduce reliance on opioid pain management; may lead to experience better rehabilitation outcomes

drug delivery Molecular Envelope Technology

Intranasal spray

Using Molecular Envelope Technology (MET), we are working to enhance enkephalin transport to the brain through an intranasal formulation. This nanotechnology enables metabolically labile peptide molecules, like enkephalin, to pass through the blood-brain barrier in order to help manage chronic pain. These enkephalin-filled nanoparticles are preloaded into a cartridge with compressed inert gas as a single dose that is compatible with our specialized device. With a simple press of a button, the device releases this powder as a long and thin plume penetrating the olfactory region.


DRUG LOADED NANOPARTICLES

The enkephalin molecule is loaded in nanoparticles


EASY-TO-USE DEVICE

No breath coordination required. Caregiver can administer to an incapacitated person


BLOOD-BRAIN BARRIER BYPASS

Drug bypasses the blood brain barrier by targeting the olfactory region

SubheadPRODUCT OVERVIEW

We are developing novel products by combining innovative drug compounds with cutting-edge delivery systems. Each product offers its own advantages to the franchise, giving healthcare providers the options and treatment alternatives they seek.

Epoladerm

Probudur

NES100

Epoladerm

Diclofenac metered-dose spray film

STATUS: CAPITAL FUNDING

Epoladerm

Diclofenac metered-dose spray film

CAPITAL FUNDING

TARGET MARKET

Topical treatment for acute musculoskeletal pain (Epoladerm) and chronic osteoarthritis knee pain (OSF200)

patch in a can

DELIVERY SYSTEM

Metered-dose spray film

BENEFITS

  • Faster drying, less messy, and better skin absorption
  • Better adhesiveness with direct skin contact
  • Better accessibility to active joints: wrists, ankles, knees and elbows
  • Improved patient compliance that could result in enhanced therapeutic outcomes

NEW DRUG APPLICATION (NDA)

As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue an accelerated 505(b)(2) New Drug Application for Epoladerm.

LEARN MORE

Probudur

Injectable long-acting bupivacaine liposomal-gel

STATUS: CAPITAL FUNDING

Probudur™

Injectable long-acting bupivacaine hydro-gel

CAPITAL FUNDING

TARGET MARKET

Post surgical knee and hip pain

DELIVERY SYSTEM

Liposomal in hydrogel encapsulation

BENEFITS

  • Single dose infiltration into the surgical site
  • Prolonged postoperative analgesia effect up to 96 hours
  • May eliminate the need for opioids and catheters after surgery
  • May reduce associated costs and length of patient stay

NEW DRUG APPLICATION (NDA)

As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue an accelerated 505(b)(2) New Drug Application for Probudur.

LEARN MORE

NES100

Endogenous enkephalin intranasal spray

STATUS: GRANT

NES100

Endogenous enkephalin intranasal spray

GRANT

TARGET MARKET

Treatment for the management of moderate to severe acute and chronic pain (NES100) and post-traumatic stress disorder (PES200)

DELIVERY SYSTEM

Endogenous enkephalin intranasal spray

BENEFITS

  • Enkephalin prodrug formulation that targets delta receptors instead of mu receptors that are responsible for the majority of undesirable side effects associated with narcotics
  • Analgesic potential to manage chronic pain without the concerns of opioid tolerance, withdrawal, respiratory depression, or euphoria

MECHANISM OF ACTION

Brain delivery: Molecular Envelope Technology (MET) allows for highly stable nanoparticles to wrap around and encapsulate hydrophobic drugs and peptides, creating a protective molecular “envelope.” MET allows for increased bioavailability of drugs that would otherwise be rapidly degraded. In the case of intranasally administered NES100, MET increases dwell time in the nares promoting delivery via the olfactory route across the blood brain barrier and into the central nervous system. Here they target the delta opioid receptors, promoting analgesia (pain relief) without characteristic mu opioid related side-effects.

Page-TitlePRODUCT PIPELINE
Franchise pipelineFranchise pipeline